



Supplemental Figure S1




Supplemental Figure S1. DCF-DA analysis of UPM treatment in HaCaT cells. (#p < 0.05 : vs control, (###p < 0.001 : vs control)

Supplemental Figure S2




Supplemental Figure S2. DCF-DA analysis of compounds against UPM treatment in HaCaT cells. (#p < 0.05 : vs control, *p < 0.05 : vs UPM)

Supplemental Figure S3




Supplemental Figure S3. Cell viability of porphyra 334

Supplemental Figure S4



Supplemental Figure S4. Western blot densitometry of CYP1A1. HaCaT cells were cotreated for 24 h with UPM (50 μg/ml) and porphyra 334 (1, 10, 100 μM). Western blotting was used to assess the expression of the CYP1A1 protein. β-actin was used as the control for whole cell lysates. (##p < 0.01 : vs control, *p < 0.05 : vs UPM **p < 0.01 : vs UPM)

Supplemental Figure S5



Supplemental Figure S5. Western blot densitometry of p-TRPV1. HaCaT cells were cotreated h with UPM (50 μg/ml) and porphyra 334 (1, 10, 100 μM) for 30, 60, 90 min. Western blotting was used to assess the expression of the p-TRPV1 protein. TRPV1 was used as the control for whole cell lysates. (#p < 0.05 : vs control, *p < 0.05 : vs UPM)